<DOC>
	<DOCNO>NCT01368263</DOCNO>
	<brief_summary>This phase II trial study impact presurgical endocrine therapy , consist goserelin letrozole anastrozole treatment premenopausal patient stage II-III estrogen receptor-positive ( ER+ ) human epidermal growth factor receptor 2 ( HER2 ) -negative breast cancer . Endocrine therapy reduces amount estrogen body . E+ breast cancer require estrogen , low level estrogen may slow stop cell growth . Giving goserelin together letrozole anastrozole surgery may enhance effectiveness , eliminate need , chemotherapy</brief_summary>
	<brief_title>Goserelin Letrozole Anastrozole Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Patient must histological cytological confirm invasive breast cancer Patient must premenopausal confirm serum estradiol level premenopausal range ( &gt; 25 pg/ml ) beginning study ; woman oral contraceptive , agent must hold two week estradiol assessment make Patient must negative serum pregnancy test within 7 day registration Patient 's tumor must ER+ without concomitant progesterone receptorpositive ( PR+ ) Allred score 6 , 7 8 ; patient &gt; 66.6 % cell stain positive conventional immunohistochemistry ( IHC ) minimum Allred score 6 eligible Patient 's tumor must HER2 negative local laboratory assessment : HER2 IHC 0 , 1+ , 2+ subsequent negative fluorescent situ hybridization ( FISH ) ( ratio &lt; 1.8 ) ; negative FISH alone absence IHC acceptable Patient must T2T4c , N , M0 breast cancer , clinical staging ( physical examination ) Patient 's primary tumor must palpable measure &gt; 2 cm tape , ruler caliper measurement least one dimension Patient must mammogram ultrasound breast within 42 day prior registration ; patient clinically palpable suspicious node , ultrasound axilla also required Patient , document treat physician , must clinically stag one following : T4 ac modify radical mastectomy negative margin goal T2 T3 conversion need mastectomy breast conservation goal T2 lumpectomy first attempt goal Patient must &gt; = 18 year old . Patient must stop take forms hormonal treatment , include oral form hormonal contraceptive method form hormone replacement therapy , least two week prior start protocol therapy Patient must agree use `` highlyeffective form nonhormonal contraception '' ( applies patient and/or partner ) Patient must willing undergo oophorectomy , indicated Patient must Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 Patient must normal organ marrow function define : Leukocytes &gt; = 3,000/mcL Absolute neutrophil count &gt; = 1,500/mcL Platelets &gt; = 100,000/mcL Total bilirubin within normal institutional limit Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamic pyruvate transaminase [ SGPT ] ) = &lt; 3.0 X institutional upper limit normal ( ULN ) Creatinine within normal institutional limit OR Creatinine clearance &gt; = 60 mL/min/1.73 m2 patient creatinine level institutional normal If patient cancer survivor , follow criterion must meet Patient undergone potentially curative therapy prior malignancy Patient must evidence prior malignancy least 5 year evidence recurrence ( except successfully treat cervical carcinoma situ , lobular carcinoma situ breast , contralateral ductal carcinoma situ ( DCIS ) treat mastectomy lumpectomy radiation without tamoxifen treatment , nonmelanoma skin cancer evidence recurrence ) Patient must deem treat physician low risk ( &lt; 30 % ) recurrence prior malignancy Patient must able understand willing sign write informed consent document Patient must inflammatory breast cancer define clinically significant erythema breast and/or document dermal lymphatic invasion ( direct skin invasion tumor peau d'orange without erythema ) Patient must prior treatment invasive breast cancer , include radiation , endocrine therapy , chemotherapy , investigational agent ; patient whose diagnosis establish incision biopsy eligible Patient must prior DCIS ipsilateral breast Patient must use tamoxifen prior contralateral DCIS Patient must evidence distant metastasis ( M1 ) imaging ; stag scan mandatory exam perform standard care throughout study period collect correlation need If patient agree undergo mastectomy lumpectomy neoadjuvant therapy , ineligible study Patient must receive investigational agent enrol another neoadjuvant clinical trial treatment exist breast cancer Pregnant and/or breastfeed woman exclude study Patient must concurrent life threaten illness Patient must undergo prior sentinel lymph node surgery ; core FNA lymph node acceptable</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>